T. Rowe Price Investment Management, Inc. Crispr Therapeutics Ag Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 3,798,103 shares of CRSP stock, worth $141 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
3,798,103
Previous 3,811,708
0.36%
Holding current value
$141 Million
Previous $150 Million
13.85%
% of portfolio
0.09%
Previous 0.09%
Shares
11 transactions
Others Institutions Holding CRSP
# of Institutions
479Shares Held
64.2MCall Options Held
2.15MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$378 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$226 Million0.04% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$103 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.54MShares$94.6 Million1.16% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.54MShares$94.6 Million0.06% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $2.9B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....